179 related articles for article (PubMed ID: 29110856)
1. External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Kataoka Y; Yamamoto Y; Otsuki T; Kaku S; Maehashi-Wada N; Fukuma S; Hirabayashi M; Nakano T; Fukuhara S
Lung Cancer; 2017 Nov; 113():88-92. PubMed ID: 29110856
[TBL] [Abstract][Full Text] [Related]
2. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
3. Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
Pass HI; Goparaju C; Espin-Garcia O; Donington J; Carbone M; Patel D; Chen Z; Feld R; Cho J; Gadgeel S; Wozniak A; Chachoua A; Leighl N; Tsao MS; de Perrot M; Xu W; Liu G
J Thorac Oncol; 2016 Jun; 11(6):900-9. PubMed ID: 26903362
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative.
Baas P; Daumont MJ; Lacoin L; Penrod JR; Carroll R; Venkatesan S; Ubhi H; Calleja A; Snee M
Lung Cancer; 2021 Dec; 162():185-193. PubMed ID: 34823894
[TBL] [Abstract][Full Text] [Related]
5. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
[TBL] [Abstract][Full Text] [Related]
6. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
8. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
10. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
[TBL] [Abstract][Full Text] [Related]
11. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.
Ceresoli GL; Grosso F; Zucali PA; Mencoboni M; Pasello G; Ripa C; Degiovanni D; Simonelli M; Bruzzone A; Dipietrantonj C; Piccolini E; Beretta GD; Favaretto AG; Giordano L; Santoro A; Botta M
Br J Cancer; 2014 Jul; 111(2):220-6. PubMed ID: 24918816
[TBL] [Abstract][Full Text] [Related]
13. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
[TBL] [Abstract][Full Text] [Related]
14. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Thieke C; Nicolay NH; Sterzing F; Hoffmann H; Roeder F; Safi S; Debus J; Huber PE
Radiat Oncol; 2015 Dec; 10():267. PubMed ID: 26715491
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
16. Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
Shaikh F; Zauderer MG; von Reibnitz D; Wu AJ; Yorke ED; Foster A; Shi W; Zhang Z; Adusumilli PS; Rosenzweig KE; Krug LM; Rusch VW; Rimner A
J Thorac Oncol; 2017 Jun; 12(6):993-1000. PubMed ID: 28341225
[TBL] [Abstract][Full Text] [Related]
17. Pleural mesothelioma: is the surgeon still there?
Opitz I; Weder W
Ann Oncol; 2018 Aug; 29(8):1710-1717. PubMed ID: 29905765
[TBL] [Abstract][Full Text] [Related]
18. Management of Malignant Pleural Mesothelioma in the Elderly Population.
Verma V; Wegner RE; Ludmir EB; Hasan S; Colonias A; Grover S; Friedberg JS; Simone CB
Ann Surg Oncol; 2019 Aug; 26(8):2357-2366. PubMed ID: 31011908
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
[TBL] [Abstract][Full Text] [Related]
20. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
Warby A; Dhillon HM; Kao S; Vardy JL
Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
